Skip to content
Screener

Arrowhead Research ARWR Net gains (losses) on investments

Net gains (losses) on investments at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$10.18M+44.4%
ALN
Alnylam PharmaceuticalsALNY
$0+100%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$16K+101%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$6.44M+68.1%
Precigen logo
PrecigenPGEN
$0+100%
RFL
Rafael Holdings, Inc.RFL
-$1.39M-46,333%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.48B+424%
Enterprise value$12.4B+425%
P/S20.1×+15.9×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Other income (expense):
Interest income16,8699,61526,56017,217
Interest expense(23,846)(21,639)(46,351)(43,285)
Loss on equity method investment(6,719)(6,719)
Gain on VIE's sale of IPR&D assets19,00019,000
Other, net(1,609)438(1,332)779
Total other income (expense)3,695(11,586)(8,842)(25,289)
(Loss) income before income tax expense and noncontrolling interest(137,565)369,616(109,293)194,501

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's net gains (losses) on investments?
Arrowhead Research (ARWR) reported net gains (losses) on investments of -$6.72M in Q1 2026.
What is the long-term trend for Arrowhead Research's net gains (losses) on investments?
Over 2 years (2021 to 2023), Arrowhead Research's net gains (losses) on investments has grown at a -100.0% compound annual growth rate (CAGR), from $1.71M to $0.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Ask your AI about Arrowhead Research's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude